Treatment of Lobular Carcinoma In Situ of the Breast in Non-Classic LCIS (Pleomorphic or Florid Variant)

Non-classic lobular carcinoma in situ (LCIS) encompasses two high-risk histologic variants — pleomorphic LCIS and florid LCIS — that carry a significantly elevated risk of upgrade to invasive disease compared with classic LCIS, and therefore require a distinct management approach.

Clinical Scenario

Pleomorphic LCIS (PLCIS) is characterised by large pleomorphic cells with marked nuclear atypia, comedonecrosis, and microcalcifications, resembling ductal carcinoma in situ. Florid LCIS (FLCIS), recognised by the WHO in 2019 as a distinct variant, is defined by marked mass-forming distention of the terminal ductal lobular unit acini with minimal intervening stroma.

Treatment Approach

Because of the high upgrade rate to invasive cancer or DCIS (30–40%), the recommended approach for non-classic LCIS involves surgical intervention with specific margin requirements.

Full margin criteria, surgical details, and the complete evidence-based regimen are available via the structured protocol.
Instant Access to Structured Evidence-Based Regimens

References

View source ↗